Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.
The U.S. Department of Energy’s Office of Science announced allocations of supercomputer access to 51 high-impact computational science projects for 2022 through its Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program.
A team including researchers from the Department of Energy’s Oak Ridge National Laboratory has developed a digital tool to better monitor a condition known as Barrett’s esophagus, which affects more than 3 million people in the United States.
Nearly a billion acres of land in the United States is dedicated to agriculture, producing more than a trillion dollars of food products to feed the country and the world. Those same agricultural processes, however, also produced an estimated 700 million metric tons of carbon dioxide equivalent in 2018, according to the U.S. Department of Agriculture.
L&N STEM Academy senior Tyler Duckworth has been named recipient of the 2021 UT-Battelle Scholarship to attend the University of Tennessee.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
The U.S. Department of Energy’s Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program is seeking proposals for high-impact, computationally intensive research campaigns in a broad array of science, engineering and computer science domains.
An analysis published in the Proceedings of the National Academy of Sciences and led by researchers from the U.S. Department of Energy’s Oak Ridge National Laboratory has received the 2021 Sustainability Science Award from the Ecological Society of America.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.